[ad_1]
Aim for the low dose dosing system with a great immune effect … “I’ll go fast”
Additional global clinical trials are expected to continue as questions arise about the effectiveness of the new vaccine against coronavirus infection (Corona 19) developed by the University of Oxford in the UK and the multinational pharmaceutical company AstraZeneca.
“Since we’ve found a way that works better, we have to prove it,” Pascal Sorio AstraZeneca CEO Sorio said in an interview with Bloomberg News on the 26th (local time). Said.
This means that more studies will be conducted on low-dose dosage regimens, in which the immunological effect of the vaccine reaches 90%.
“It’s going to be another international study,” Sorio said. “We already know that it works very well, so only a small number of patients will be able to proceed as quickly as necessary.”
He predicted that this would not delay approval of the vaccine in the UK and the European Union.
In the US, approval is expected to take longer.
Previously, AstraZeneca and the University of Oxford announced on the 23rd that the average immunity effect was 70% as a result of initial data analysis from a phase 3 clinical trial of the vaccine they are developing.
Participants who first administered half the dose of the vaccine first and a full dose one month later had a prophylactic effect of 90%, and those who received the full dose of both doses were 62%.
The researchers said the cause of the different immunological effects depending on the dose is still unknown.
At a press conference, AstraZeneca Vice President Mene Pangalos admitted that it was an inadvertent mistake and said: “It was a coincidence that we received half the dose.”
Furthermore, it was belatedly revealed that all participants who received half the dose in the first dose were under 55 years of age and did not have an elderly population.
As the suspicion of omission of other key information was added, questioning the reliability of the vaccine, it appears that the decision was made to carry out further tests.
/ yunhap news
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution
